Skip to content
lifestyle.womensconference.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Zealand Pharma
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
May 22, 2026
Zealand Pharma announces Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial
May 21, 2026
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
May 21, 2026
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
May 20, 2026
Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026
May 20, 2026
Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations
April 29, 2026
Zealand Pharma to participate in upcoming investor conferences in March 2026
March 9, 2026
Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity
March 5, 2026
Zealand Pharma convenes its Annual General Meeting 2026
February 19, 2026
Zealand Pharma Announces Financial Results for the Full Year 2025
February 19, 2026
←
Previous Page
1
…
4
5
6